What the FDA labels say about taking them together
Clopidogrel and enzalutamide
Enzalutamide's FDA label (Xtandi) of May 25, 2021 names clopidogrel in its drug interactions section; the clopidogrel label PlainMeds reads does not name enzalutamide. The enzalutamide label: “Concomitant use of XTANDI with narrow therapeutic index drugs that are metabolized by CYP3A4, CYP2C9 and CYP2C19 should be avoided, as enzalutamide may decrease their exposure.”
Check it at the source: the clopidogrel FDA label on DailyMed (effective May 30, 2025, Sanofi-Aventis U.S. LLC); the enzalutamide FDA label on DailyMed (effective July 28, 2026, Astellas Pharma US, Inc.).
What does the clopidogrel label say about enzalutamide?
Clopidogrel's label (effective May 30, 2025) does not name enzalutamide in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Plavix), Sanofi-Aventis U.S. LLC, effective May 30, 2025 (SPL set de8b0b67-eb25-4684-83b5-7ad785314227), via openFDA; the full label on DailyMed
What does the enzalutamide label say about clopidogrel?
Xtandi label (Astellas Pharma US, Inc., May 25, 2021), drug interactionsConcomitant use of XTANDI with narrow therapeutic index drugs that are metabolized by CYP3A4 (e.g., alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus and tacrolimus), CYP2C9 (e.g., phenytoin, warfarin) and CYP2C19 (e.g., S-mephenytoin, clopidogrel) should be avoided, as enzalutamide may decrease their exposure.
Source: FDA drug label (Xtandi, NDA213674), Astellas Pharma US, Inc., effective May 25, 2021 (SPL set 381cd215-78c9-4208-8595-7ae7a279b236), via openFDA
Source: FDA drug label (Xtandi), Astellas Pharma US, Inc., effective July 28, 2026 (SPL set b129fdc9-1d8e-425c-a5a9-8a2ed36dfbdf), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Clopidogrel | Enzalutamide | |
|---|---|---|
| Labeled for | Heart attack and coronary artery disease, Angina | Prostate cancer |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.0472 per tablet 75 mg tablet | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once